Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
2(100.0%)
2Total
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT03025399Early Phase 1Unknown

Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy

Role: collaborator

NCT03009864Early Phase 1Unknown

The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage

Role: collaborator

All 2 trials loaded